OncoMatch/Clinical Trials/NCT06680661
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Is NCT06680661 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for acute myelogenous leukemia.
Treatment: Cyclophosphamide · Fludarabine · Thiotepa · Double Umbilical Cord Transplant · Tacrolimus · Mycophenolate Mofetil · Abatacept — The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Prior therapy
Cannot have received: autologous or allogenic stem cell transplant
Exception: allowed if > 12 months prior
Prior autologous or allogenic stem cell transplant within the preceding 12 months
Lab requirements
Kidney function
Creatinine clearance ≥ 50ml/min
Liver function
Bilirubin ≤ 2X institutional upper limit of normal unless Gilbert syndrome; AST (SGOT) ≤ 3X institutional upper limit of normal; ALT (SGPT) ≤ 3X institutional upper limit of normal
Cardiac function
Left ventricular ejection fraction ≥ 50
Patients with inadequate Organ Function as defined by: Creatinine clearance < 50ml/min; Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome; AST (SGOT) > 3X institutional upper limit of normal; ALT (SGPT) > 3X institutional upper limit of normal; Pulmonary function: DLCOc < 60% normal; Cardiac: left ventricular ejection fraction < 50
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify